Prognostic significance of atypical papillary urothelial hyperplasia

Swierczynski, Sharon L.; Epstein, Jonathan I.

doi:10.1053/hupa.2002.124031

Cited by 30 publications

(14 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most of their patients were men (11 men and 5 women) with a mean age of 67.5 years (range, 40-89 years). In a subsequent study, Swierczynski and Epstein [21] reported 15 cases of papillary urothelial hyperplasia with varying degrees of atypia ranging from dysplasia to flat carcinoma in situ (atypical papillary urothelial hyperplasia). Most of the patients in Swierczynski's study developed high-grade urothelial neoplasms.…”

Section: Papillary Urothelial Hyperplasiamentioning

confidence: 96%

Urothelial dysplasia and other flat lesions of the urinary bladder: clinicopathologic and molecular features

et al. 2010

View full text Add to dashboard Cite

Section: Papillary Urothelial Hyperplasiamentioning

confidence: 96%

Urothelial dysplasia and other flat lesions of the urinary bladder: clinicopathologic and molecular features

et al. 2010

View full text Add to dashboard Cite

“…The majority of patients are men, with a mean age of 67 years. Swierczynski et al reported 15 cases of papillary urothelial hyperplasia with varying degrees of atypia ranging from dysplasia to flat CIS (atypical papillary urothelial hyperplasia) [75].…”

Section: Papillary Urothelial Hyperplasiamentioning

confidence: 99%

The origins of urothelial carcinoma

Liu

Davidson²,

MacLennan

et al. 2010

Expert Review of Anticancer Therapy

View full text Add to dashboard Cite

It is now widely believed that there are two major pathways for urothelial carcinogenesis. One pathway usually involves mutation of FGF receptor 3 and gives rise to low-grade papillary tumors that frequently recur but seldom invade. By contrast, high-grade urothelial malignancies, including high-grade papillary urothelial carcinoma and urothelial carcinoma in situ (CIS) usually exhibit deletions or mutations of TP53. Urothelial CIS is the most likely precursor of high-grade invasive bladder cancer. It is a 'flat lesion' that may be relatively inconspicuous at cystoscopy, or even endoscopically undetectable. The clinical hazards associated with this elusive and biologically dangerous neoplasm have been increasingly well documented since the original studies by Melicow in 1952. Primary or secondary urothelial dysplasia is even more challenging to detect and diagnose than CIS. It is theorized that dysplasia may antedate the onset of CIS, but support for the putative progression of dysplasia to CIS is found in fewer than 20% of cases. Since many benign urothelial changes may resemble CIS at cystoscopy, in biopsies and even with molecular profiling, care must be exercised when making a diagnosis of CIS. For patients whose screening tests are worrisome for the presence of premalignant urothelial disease, newer bladder imaging modalities, including Raman spectral imaging and optical coherence tomography, may enable improved biopsy site selection. In this article, we discuss the above-noted topics, as well as other related issues, such as the possible role of papillary urothelial hyperplasia as a preneoplastic lesion and the roles of cancer stem cells and field cancerization in urothelial carcinogenesis.

show abstract

“…A number of reports have described similar changes in urothelial neoplasia induced by intravesical therapies, termed as ‘truncated papillae of treated papillary carcinoma’ 40 or as ‘atypical papillary urothelial hyperplasia.’ 41 Such changes may be induced by the local abrasive effect of intravesical agents. 40 Under increased clinical scrutiny and sampling of patients following contemporary protocols, such lesions pose a challenge to the practicing pathologist regarding diagnostic approach and terminology.…”

Section: Icud Recommendation: Approach and Terminology For Incipient mentioning

confidence: 99%

Update for the practicing pathologist: The International Consultation On Urologic Disease-European association of urology consultation on bladder cancer

et al. 2015

View full text Add to dashboard Cite

The International Consultations on Urological Diseases are international consensus meetings, supported by the World Health Organization and the Union Internationale Contre le Cancer, which have occurred since 1981. Each consultation has the goal of convening experts to review data and provide evidence-based recommendations to improve practice. In 2012, the selected subject was bladder cancer, a disease which remains a major public health problem with little improvement in many years. The proceedings of the 2nd International Consultation on Bladder Cancer, which included a ‘Pathology of Bladder Cancer Work Group,’ have recently been published; herein, we provide a summary of developments and consensus relevant to the practicing pathologist. Although the published proceedings have tackled a comprehensive set of issues regarding the pathology of bladder cancer, this update summarizes the recommendations regarding selected issues for the practicing pathologist. These include guidelines for classification and grading of urothelial neoplasia, with particular emphasis on the approach to inverted lesions, the handling of incipient papillary lesions frequently seen during surveillance of bladder cancer patients, descriptions of newer variants, and terminology for urine cytology reporting.

show abstract

Prognostic significance of atypical papillary urothelial hyperplasia

Cited by 30 publications

References 10 publications

Urothelial dysplasia and other flat lesions of the urinary bladder: clinicopathologic and molecular features

Urothelial dysplasia and other flat lesions of the urinary bladder: clinicopathologic and molecular features

The origins of urothelial carcinoma

Update for the practicing pathologist: The International Consultation On Urologic Disease-European association of urology consultation on bladder cancer

Contact Info

Product

Resources

About